Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Longevity Health Holdings, Inc.CTCX · Entity 8659 | Chief Medical Officer | July 14, 2023 | July 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Longevity Health Holdings, Inc.
Report date July 14, 2023 · Filed July 19, 2023
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2023 Filed Jul 19, 2023 00:35 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 12,309 | Not disclosed Strike: $2.60 | Not disclosed |
DisclosureSEC source: 0001062993-23-015054 · form4.xml · derivative · entry 7 Hart James C · CIK 0001984335 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,309 Underlying: Common Stock · 12,309 shares Expires 2032-12-15 F8 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F7 · derivative.exercise_date: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on December 15, 2022, which vest as follows: 25% vested on December 15, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:35 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 12,309 | Not disclosed Strike: $2.11 | Not disclosed |
DisclosureSEC source: 0001062993-23-015054 · form4.xml · derivative · entry 6 Hart James C · CIK 0001984335 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,309 Underlying: Common Stock · 12,309 shares Expires 2032-07-13 F8 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F6 · derivative.exercise_date: Options to purchase 12,309 shares of common stock of Legacy Carmell granted on July 13, 2022, which vest as follows: 25% vested on July 13, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:35 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 109,937 | Not disclosed Strike: $2.11 | Not disclosed |
DisclosureSEC source: 0001062993-23-015054 · form4.xml · derivative · entry 5 Hart James C · CIK 0001984335 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,937 Underlying: Common Stock · 109,937 shares Expires 2031-09-23 F8 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F5 · derivative.exercise_date: Options to purchase 109,937 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:35 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 9,161 | Not disclosed Strike: $2.27 | Not disclosed |
DisclosureSEC source: 0001062993-23-015054 · form4.xml · derivative · entry 4 Hart James C · CIK 0001984335 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,161 Underlying: Common Stock · 9,161 shares Expires 2030-07-17 F8 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F4 · derivative.exercise_date: Options to purchase 9,161 shares of common stock of Legacy Carmell granted on July 17, 2020, which vest as follows: 25% vested on July 17, 2021, July 17, 2022 and July 17, 2023 and the remaining 25% becomes vested in 12 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:35 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 5,318 | Not disclosed Strike: $2.27 | Not disclosed |
DisclosureSEC source: 0001062993-23-015054 · form4.xml · derivative · entry 3 Hart James C · CIK 0001984335 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,318 Underlying: Common Stock · 5,318 shares Expires 2029-07-19 F8 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F3 · derivative.exercise_date: Options to purchase 5,318 shares of common stock of Legacy Carmell granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% will vest on July 19, 2023. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:35 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 2,080 | Not disclosed Strike: $1.79 | Not disclosed |
DisclosureSEC source: 0001062993-23-015054 · form4.xml · derivative · entry 2 Hart James C · CIK 0001984335 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,080 Underlying: Common Stock · 2,080 shares Expires 2027-06-20 F8 · price: As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:35 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantCommon Stock | 37,307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-015054 · form4.xml · nonDerivative · entry 1 Hart James C · CIK 0001984335 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,307 F1 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each share of common stock of Legacy Carmell was exchanged for 0.06154 shares of common stock of Carmell Therapeutics Corporation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.